
    
      In dose cohort 1, patients will be treated in cycles, which are defined by APG-1252
      intravenous administration on Days 1, 4, 8, 11, 15, 18 and 22, over a 28-day cycle the start
      dose is 10mg.

      After dose escalation to 240mg twice weekly in dose cohort 1, dose cohort 2 will be performed
      with dose cohort 1 parallelly, patients will be treated in the same 28-day-cycles, APG-1252
      intravenous administration on Days 1, 8, 15, and 22, the start dose is 240mg.

      In both dose cohorts' patients could continue to receive cycles of APG-1252 until disease
      progress or unacceptable toxicity.

      Study drug will be administered by intravenous infusion for 30 minutes at the investigational
      site by site staff.
    
  